Lupin has announced the approval of its Formoflo-G glypocyrronium / formoterol / fluticasone propionate MDI for the treatment of COPD by the Drug Controller General of India (DCGI) and the subsequent launch of the inhaler in India. According to Lupin, the twice-daily Formoflo-G is the country’s first triple combination MDI for COPD. Lupin previously launched a triple combination vilanterol / fluticasone furoate / glycopyrronium DPI called Vilfuro-G for the treatment of COPD in India in 2023.
Lupin Managing Director Nilesh Gupta commented, “As respiratory diseases continue to impact millions across India, access to effective therapies remains critical. Formoflo-G MDI reflects our commitment to addressing unmet patient needs through differentiated, high-quality therapies. By combining innovation with accessibility, we aim to improve outcomes for patients living with respiratory diseases.”
Lupin President, India Region Formulations, Rajeev Sibal added, “Formoflo-G MDI marks an important addition to our respiratory portfolio, bringing together three established therapies in a single inhaler. It strengthens Lupin’s respiratory portfolio and provides healthcare professionals with an important treatment option for appropriate COPD patients. It reflects our commitment to delivering innovative, high-quality therapies that help improve patient outcomes.”
Read the Lupin press release
